{
  "url": "https://www.law.cornell.edu/regulations/new-york/14-NYCRR-800.6",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 14 ยง 800.6 - Access to Medication Assisted Treatment",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 14 ยง 800.6 - Access to Medication Assisted Treatment\n\nState Regulations\n(a) All programs certified pursuant to this\n\nChapter shall facilitate expeditious access to medication assisted treatment, based on the clinical need and preference of the patient, through direct\nprovision of the medication, contracting with private prescribing professionals\nor linkage agreements with other Office certified programs. Such agreements\nmust ensure access sufficient to meet patient needs without undue barriers such\nas long waiting periods for appointments or waiting lists. (b) All doctors, physician assistants and\nnurse practitioners employed in a treatment program certified pursuant to this\n\nChapter must have a federal DATA 2000 waiver to prescribe\nbuprenorphine. (c) All programs\nmust allow for provision of medication assisted treatment and may not deny\nadmission based on use of medication. Programs must continue access to opioid\nfull and partial agonist treatment and plan for the continuity of medication\nadministration. (d) All programs\nmust maintain an emergency medical kit at each certified or funded location; such kit must include basic first aid and naloxone emergency overdose\nprevention kit(s) in a quantity sufficient to meet the needs of the program and\nthat are available for use during all program hours of operation. (e) Each program that dispenses medications\nmust develop and implement a diversion control plan (DCP) as part of its\nquality improvement plan, such DCP must include specific measures to reduce the\npossibility for diversion of controlled substances from legitimate treatment\nuse and shall assign specific responsibility to the medical and administrative\nstaff of the program for carrying out the diversion control measures and\nfunctions described in the DCP. (f) Programs shall provide access to Medication for Addiction Treatment (MAT) for\n\nSubstance Use Disorder in accordance with this Part, the Part under which the\nprogram is certified or otherwise authorized, and guidance issued by the\n\nOffice. (1)\n\nAll programs shall maintain a\npatient with substance use disorder on approved medication, including those\nfederal Food and Drug Administration (FDA) approved medications to treat\nsubstance use disorder, if deemed clinically appropriate and in collaboration\nwith the patient's existing provider, and with the patient's consent, in\naccordance with federal and state rules and guidance issued by the Office. The\nprogram shall document such contact with the existing program or practitioner\nprescribing such medications. (2)\n\nTo facilitate access to full opioid agonist medication for patients who are\nmaintained on such medication at the time of admission or who choose to start\nsuch medication during admission, all programs shall develop a formal agreement\nwith at least one Opioid Treatment Program (OTP) certified by the Office to\nfacilitate patient access to full opioid agonist medication, if clinically\nappropriate. Such agreements shall address the program and the OTPs\nresponsibilities to facilitate patient access to such medication in accordance\nwith guidance issued by the Office. (3)\n\nAll programs shall provide FDA approved\nmedications to treat substance use disorders to an existing patient or\nprospective patient seeking admission to an Office certified program in\naccordance with all federal and state rules and guidance issued by the\n\nOffice. (4)\n\nAll programs shall\nprovide education to an existing patient or prospective patient with substance\nuse disorder about FDA approved medications for the treatment of substance use\ndisorder if the patient is not already taking such medications, including the\nbenefits and risks. The program shall document such discussion and the outcome\nof such discussion, including a patient's preference for or refusal of\nmedication, in the patient's record. (5)\n\nAll programs shall ensure that the patient's discharge plan\nincludes an appointment with a treatment provider or program that can continue\nthe medication post-discharge. (g) Programs shall provide access to overdose prevention\neducation, training and supplies in accordance with this Part, the Part under\nwhich the program is certified, funded or otherwise authorized and/or guidance\nissued by the Office. (1)\n\nAll programs must\nmaintain an emergency medical kit at each certified or funded location; such\nkit must include basic first aid and naloxone emergency overdose prevention\nkit(s) in a quantity sufficient to meet the needs of the program and that are\navailable for use during all program hours of operation. (2)\n\nAll programs shall provide overdose\nprevention education and naloxone education and training to a patient or\nprospective patient, and their significant other(s), in accordance with\nguidance issued by the Office. (3)\n\nAll programs shall make available to patients and prospective patients, and\ntheir significant other(s), a naloxone kit or prescription as appropriate, in\naccordance with guidance issued by the Office. Notes\nN.Y. Comp. Codes\nR. & Regs. Tit. 14\nยง\n800.6\n\nAdopted\n\nNew\n\nYork State Register May 29, 2019/Volume XLI, Issue 22, eff. 5/29/2019\n\nAmended\n\nNew\n\nYork State Register February 16, 2022/Volume XLIV, Issue 07, eff. 2/16/2022\n\nAmended\n\nNew\n\nYork State Register September 14, 2022/Volume XLIV, Issue 37, eff. 10/1/2022\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. No prior version found.",
  "url_type": "regulation",
  "source_index": 48934
}